Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry. In today’s Pharmaceutical Executive Daily, MJH Life Sciences CEO, Mike Hennessy Jr. examines why pharma and medtech still struggle to deliver truly integrated healthcare solutions, questions emerge around U.S. funding tied to global vaccine policy shifts, and the FDA approves a new treatment option for adults with presbyopia. In a new analysis, MJH Life Sciences chairman Mike Hennessy Jr. highlights the persistent disconnect between pharma and medtech, despite shared goals around outcomes, efficiency, and patient-centered care. Meanwhile, a new report underscores how U.S. funding for a major global vaccine organization is increasingly tied to decisions around the removal of thimerosal from vaccines. Thanks for listening to Pharmaceutical Executive Daily.